{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:19:08Z","timestamp":1790662748665,"version":"4.1.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>Deoxycholic acid (DCA; ATX-101) injection was approved for the treatment of mild-to-moderate convexity associated with submental fat in 2015.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To evaluate the experience with DCA injections in a clinical practice setting.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MATERIALS AND METHODS<\/jats:title>\n            <jats:p>This ongoing, prospective, single-center, single-arm, observational study evaluated 100 consecutive patients treated with subcutaneous DCA (2 mg\/cm<jats:sup>2<\/jats:sup>) injections (maximum 6 sessions at \u22651-month intervals). Treatment response was assessed using the clinician-reported submental fat rating scale (CR-SMFRS) and confirmed by independent physician review of photographs at 1 and 5 to 7 weeks after treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Since the previous published report, 17 patients have undergone additional treatment sessions, with a total of 100 patients having undergone 195 treatment sessions: 41, 36, 14, 6, 2, and 1 patient underwent 1, 2, 3, 4, 5, and 6 sessions, respectively. Overall, 91.7% of patients in the single treatment session group and 100% in the multiple treatment session group had an improvement of \u22651 point on the CR-SMFRS. The mean (SD) duration of local edema, numbness, and tenderness after treatment was 7.1 (5.1), 27.9 (11.3), and 3.5 (3.5) days, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Deoxycholic acid injections were generally well tolerated, and \u22652 treatment sessions were required to achieve the desired aesthetic goal in a private practice setting.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000001811","type":"journal-article","created":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T12:56:16Z","timestamp":1550753776000},"page":"1285-1293","source":"Crossref","is-referenced-by-count":21,"title":["Real-World Experience With 100 Consecutive Patients Undergoing Neck Contouring With ATX-101 (Deoxycholic Acid): An Updated Report With A 2-Year Analysis"],"prefix":"10.1097","volume":"45","author":[{"given":"Sachin M.","family":"Shridharani","sequence":"first","affiliation":[{"name":"LUXURGERY, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1517\/13543776.2016.1102888","article-title":"Formulations of deoxycholic for therapy: a patent review (2011\u20132014)","volume":"25","author":"Hwang","year":"2015","journal-title":"Expert Opin Ther Pat"},{"key":"R6-20230814","first-page":"1001","article-title":"Detergent effects of sodium deoxycholate are a major feature of an injectable phosphatidylcholine formulation used for localized fat dissolution","volume":"30","author":"Rotunda","year":"2004","journal-title":"Dermatol Surg"},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.lfs.2014.05.013","article-title":"The role of phosphatidylcholine and deoxycholic acid in inflammation","volume":"108","author":"Chung","year":"2014","journal-title":"Life Sci"},{"key":"R8-20230814","first-page":"178","article-title":"Action of sodium deoxycholate on subcutaneous human tissue: local and systemic effects","volume":"33","author":"Yagima Odo","year":"2007","journal-title":"Dermatol Surg"},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/bjd.12695","article-title":"Reduction of unwanted submental fat with ATX-101 (deoxycholic acid), an adipocytolytic injectable treatment: results from a phase III, randomized, placebo-controlled study","volume":"170","author":"Rzany","year":"2014","journal-title":"Br J Dermatol"},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1111\/jdv.12377","article-title":"Efficacy, patient-reported outcomes and safety profile of ATX-101 (deoxycholic acid), an injectable drug for the reduction of unwanted submental fat: results from a phase III, randomized, placebo-controlled study","volume":"28","author":"Ascher","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/DSS.0000000000000578","article-title":"REFINE-1, a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial with ATX-101, an injectable drug for submental fat reduction","volume":"42","author":"Jones","year":"2016","journal-title":"Dermatol Surg"},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00266-014-0364-9","article-title":"Results from a pooled analysis of two European, randomized, placebo-controlled, phase 3 studies of ATX-101 for the pharmacologic reduction of excess submental fat","volume":"38","author":"McDiarmid","year":"2014","journal-title":"Aesthetic Plast Surg"},{"key":"R13-20230814","first-page":"123","article-title":"A pooled analysis of the safety and efficacy results of the multicenter, double-blind, randomized, placebo-controlled phase 3 REFINE-1 and REFINE-2 trials of ATX-101, a submental contouring injectable drug for the reduction of submental fat","volume":"134","author":"Dayan","year":"2014","journal-title":"Plast Reconstr Surg"},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/DSS.0000000000001133","article-title":"Early experience in 100 consecutive patients with injection adipocytolysis for neck contouring with ATX-101 (deoxycholic acid)","volume":"43","author":"Shridharani","year":"2017","journal-title":"Dermatol Surg"},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jdcr.2017.02.021","article-title":"Alopecia after injection of ATX-101 for reduction of submental fat","volume":"3","author":"Souyoul","year":"2017","journal-title":"JAAD Case Rep"},{"issue":"Suppl 1","key":"R16-20230814","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1097\/DSS.0000000000000870","article-title":"Overview of ATX-101 (deoxycholic acid injection): a nonsurgical approach for reduction of submental fat","volume":"42","author":"Dayan","year":"2016","journal-title":"Dermatol Surg"},{"issue":"Suppl 1","key":"R17-20230814","doi-asserted-by":"crossref","first-page":"S288","DOI":"10.1097\/DSS.0000000000000908","article-title":"Management of patient experience with ATX-101 (deoxycholic acid injection) for reduction of submental fat","volume":"42","author":"Dover","year":"2016","journal-title":"Dermatol Surg"},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1097\/DSS.0000000000000964","article-title":"Management of patient experience with ATX-101 (deoxycholic acid injection) for reduction of submental fat","volume":"42","author":"Humphrey","year":"2016","journal-title":"Dermatol Surg"},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jaad.2016.04.028","article-title":"ATX-101 for reduction of submental fat: a phase III randomized controlled trial","volume":"75","author":"Humphrey","year":"2016","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000001811","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T19:37:02Z","timestamp":1692041822000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000001811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000001811","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}